E303 for Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 149 (estimated)
- Sponsor
- Samsung Bioepis Co., Ltd. · Industry
This trial is looking for people with advanced solid tumors. Participants will receive a new treatment called E303 to see how safe and effective it is.
You may be able to join if
- I have advanced solid tumors that have not responded to standard treatment.
- I have been told that I cannot have standard treatment.
- I have refused standard treatment.
- I have tumors that cannot be surgically removed.
You may not be able to join if
- I have spinal cord compression.
- I have active brain metastases.
- I have leptomeningeal disease.
- I have had significant bleeding events.
- I have heart problems.
- I have an active autoimmune disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Loading trial locations…